Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology.

@article{Hampel2018RevolutionOA,
  title={Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology.},
  author={Harald Hampel and Nicola Toschi and Claudio Babiloni and Filippo Baldacci and Keith L. Black and Arun L. W. Bokde and Ren{\'e} Sosata Bun and Francesco Cacciola and Enrica Cavedo and Patrizia Andrea Chiesa and Olivier Colliot and Cristina-Maria Coman and Bruno Dubois and Andrea Duggento and Stanley Durrleman and Maria Teresa Ferretti and Nathalie George and R{\'e}my Genthon and Marie-Odile Habert and Karl Herholz and Yosef Koronyo and Maya Koronyo-Hamaoui and Foudil Lamari and Todd Langevin and St{\'e}phane Leh{\'e}ricy and Jean Lorenceau and Christian N{\'e}ri and Roberto Nistic{\`o} and Francis Nyasse-Messene and Craig W. Ritchie and Simone Rossi and Emiliano Santarnecchi and Olaf Sporns and Steven R. Verdooner and Andrea Vergallo and Nicolas Villain and Erfan Younesi and Francesco Garaci and Simone Lista},
  journal={Journal of Alzheimer's disease : JAD},
  year={2018},
  volume={64 s1},
  pages={
          S47-S105
        }
}
The Precision Neurology development process implements systems theory with system biology and neurophysiology in a parallel, bidirectional research path: a combined hypothesis-driven investigation of systems dysfunction within distinct molecular, cellular, and large-scale neural network systems in both animal models as well as through tests for the usefulness of these candidate dynamic systems biomarkers in different diseases and subgroups at different stages of pathophysiological progression… 

Figures and Tables from this paper

Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer’s disease

TLDR
Systems biology-based approaches are poised to identify relevant AD “signatures” through multifactorial and interindividual variability, allowing us to decipher disease pathophysiology and etiology, and innovative biomarker-drug codevelopment strategies will be the road ahead towards effective disease-modifying drugs.
Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
TLDR
This Review summarizes the efforts of an international working group that aimed to survey the current landscape of blood-based AD biomarkers and outlines operational steps for an effective academic–industry co-development pathway from identification and assay development to validation for clinical use.
Developing the ATX(N) classification for use across the Alzheimer disease continuum
TLDR
A state-of-the-art summary of the potential contexts of use of these systems in AD clinical trials and future clinical practice is provided and current challenges related to the validation, standardization and qualification process are discussed.
From Multi-Omics Approaches to Precision Medicine in Amyotrophic Lateral Sclerosis
TLDR
The most significant contributions of omics technologies in unraveling the biological heterogeneity of ALS are discussed, highlighting how these approaches are revealing diagnostic, prognostic and therapeutic targets for future personalized interventions.
The role of synaptic biomarkers in the spectrum of neurodegenerative diseases
TLDR
Synaptic biomarkers may serve different context-of-use in AD and other NDD including prognosis, diagnosis, and tracking synaptic damage – a critical pathophysiological mechanism in NDD – thus representing reliable tools for a precision medicine-oriented approach to NDD.
The Alzheimer Precision Medicine Initiative.
TLDR
The scientific breakthrough advances and the pillars of the theoretical and conceptual development leading to the Alzheimer Precision Medicine Initiative are presented.
microRNA-Based Biomarkers in Alzheimer’s Disease (AD)
TLDR
The significantly heterogeneous nature of miRNA expression and complexity in AD tissues and biofluids is highlighted and information may be extracted from these data to be used as a diagnostic, prognostic and/or screening tools across the entire continuum of AD.
...
...

References

SHOWING 1-10 OF 709 REFERENCES
Systems approach to neurodegenerative disease biomarker discovery.
TLDR
Current proteomic and nucleic acid technologies involved in the discovery of biomarkers of neurodegenerative diseases, particularly Alzheimer's, Parkinson's, Huntington's, and prion diseases are summarized.
PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease.
TLDR
The precision medicine strategy facilitates a paradigm shift in Neuroscience and AD research and development away from the classical "one-size-fits-all" approach in drug discovery towards biomarker guided "molecularly" tailored therapy for truly effective treatment and prevention options.
Perspectives for multimodal neurochemical and imaging biomarkers in Alzheimer's disease.
TLDR
In vivo markers of key events in AD pathogenesis integrated into a heuristic framework that makes strong predictions on pattern of multimodal biomarkers in different stages of AD are available for the first time.
Towards a Pathway Inventory of the Human Brain for Modeling Disease Mechanisms Underlying Neurodegeneration.
TLDR
This work has created a pathway terminology system by combining signaling pathways and biological events to ensure a broad coverage of the entire pathway knowledge domain and demonstrates the power of this resource by mapping literature-derived signaling pathways onto their corresponding anatomical regions in the human brain under healthy and Alzheimer's disease states.
Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: The Present and the Future
TLDR
The present state of the art and the future challenges in the search of CSF biomarkers for AD are discussed, highlighting the relevance of translational research for unbiased investigations of numerous putative markers that may be informative with regard to AD.
The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.
TLDR
Six AD biomarkers are sufficiently validated and partly qualified to be incorporated into operationalized clinical diagnostic criteria and use in primary and secondary prevention trials, and novel promising hypothesis-driven and exploratory biochemical, genetic, electrophysiological, and neuroimaging markers for use in clinical trials are being developed.
A Precision Medicine Initiative for Alzheimer’s disease: the road ahead to biomarker-guided integrative disease modeling
TLDR
It is hypothesized that successful realization of PM in AD and other neurodegenerative diseases will result in breakthrough therapies, such as in oncology, with optimized safety profiles, better responder rates and treatment responses, particularly through biomarker-guided early preclinical disease-stage clinical trials.
Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement
TLDR
To effectively test preventive compounds for AD and bring therapy to affected individuals as early as possible there is an urgent need for a concerted collaboration among worldwide academic institutions, industry, and regulatory bodies with the aim of establishing networks for the identification and qualification of multi-modal biological disease markers.
...
...